1267P Clinical utility of ctDNA for detection of EGFR, ALK, BRAFV600E alterations and resistance mutations in patients with NSCLC at failure to targeted therapy

M Riudavets Melià ,A Gazzah,J-C Soria,V Lamberts,Fabrice Barlési ,David Planchard ,Christophe Massard ,Clive Morris ,Miguel Suárez ,Ludovic Lacroix ,Cécile Jovelet ,P Martin Romano,Damien Vasseur ,Mihaela Aldea ,Karen Howarth ,Benjamin Besse ,Charles Naltet ,A.m Grecea ,Pernelle Lavaud ,Laura Mezquita

doi:10.1016/j.annonc.2021.08.1869

1267P Clinical utility of ctDNA for detection of EGFR, ALK, BRAFV600E alterations and resistance mutations in patients with NSCLC at failure to targeted therapy

M Riudavets Melià , A Gazzah + Show 18 more

Open Access

https://doi.org/10.1016/j.annonc.2021.08.1869

Copy DOI

Journal: Annals of Oncology	Publication Date: Sep 1, 2021
Citations: 1	License type: publisher-specific-oa

Affiliation: Institut Gustave Roussy, Hospital Clínic de Barcelona

#Resistance Mutations In Patients #Non-small Cell Lung Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

The comprehensive genomic profile by next generation sequencing (NGS) of circulating tumour DNA (ctDNA) can identify a wide spectrum of genomic alterations (GAs) in non-small cell lung cancer (NSCLC). We aimed to assess the clinical utility of amplicon-based ctDNA NGS for detecting GAs and resistance mutations at time of progression (PD).

Full Text